Table 1 Baseline characteristics
Parameter | Experimental Group (n = 34) | Control group (n = 30) | P value |
|---|---|---|---|
Age(year) | 62.7 ± 10.9 | 61.5 ± 8.5 | 0.63 |
Sex(male/Female) | 14/20 | 15/15 | 0.62 |
Tumor differentiation (Medium and low/highly) | 9/25 | 8/22 | 0.99 |
Max Diameter (mm) | 16.6 ± 6.7 | 17.6 ± 5.5 | 0.53 |
Obstruction length (mm) | 48.5 ± 10.7 | 52.2 ± 8.0 | 0.13 |
Bismuth type (I/II/III/IV) | 3/6/18/7 | 4/5/17/4 | 0.84 |
ECOG score (0/1/2) | 8/8/18 | 5/10/15 | 0.63 |
Distant metastasis(Yes/no) | 13/21 | 15/15 | 0.34 |
Biochemical index | |||
 White blood cell (× 109/L) | 6.4 ± 1.6 | 6.5 ± 1.6 | 0.76 |
 Platelet(× 109/L) | 175.1 ± 29.7 | 168.0 ± 24.1 | 0.30 |
 Hemoglobin(g/L) | 126.2 ± 16.5 | 121.7 ± 12.2 | 0.22 |
 Albumin (g/L) | 39.1 ± 2.7 | 38.7 ± 2.3 | 0.57 |
 Glutamic pyruvic transaminase (U/L) | 88.2 ± 35.8 | 97.0 ± 40.0 | 0.36 |
 Glutamic oxaloacetic transaminase (U/L) | 85.0 ± 36.5 | 98.3 ± 41.0 | 0.18 |
 Total bilirubin (µmol/L) | 168.1 ± 53.0 | 184.6 ± 24.1 | 0.22 |
 Direct bilirubin (µmol/L) | 131.5 ± 46.0 | 139.2 ± 42.8 | 0.50 |
 Prothrombin time(s) | 17.9 ± 2.9 | 18.0 ± 2.7 | 0.90 |
 Serum CA19-9 (U/ml) | 592.2 ± 253.8 | 507.4 ± 245.3 | 0.18 |
 Follow up Chemotherapy (1–3/4–6 courses) | 23/11 | 24/6 | 0.26 |